Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty

Anti-PARK7/DJ1 Antibody (9Q473)

😃Good
Catalog No. TMAC-03067

Anti-PARK7/DJ1 Antibody (9Q473) is a Rabbit antibody targeting PARK7/DJ1. Anti-PARK7/DJ1 Antibody (9Q473) can be used in WB,ICC/IF,IHC,IP,FCM.

Anti-PARK7/DJ1 Antibody (9Q473)

Anti-PARK7/DJ1 Antibody (9Q473)

😃Good
Catalog No. TMAC-03067
Anti-PARK7/DJ1 Antibody (9Q473) is a Rabbit antibody targeting PARK7/DJ1. Anti-PARK7/DJ1 Antibody (9Q473) can be used in WB,ICC/IF,IHC,IP,FCM.
Pack SizePriceAvailabilityQuantity
50 μL$2967-10 days
100 μL$4967-10 days
Add to Cart
Add to Quotation
Bulk & Custom
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Questions
View More

Product Introduction

Bioactivity
Description
Anti-PARK7/DJ1 Antibody (9Q473) is a Rabbit antibody targeting PARK7/DJ1. Anti-PARK7/DJ1 Antibody (9Q473) can be used in WB,ICC/IF,IHC,IP,FCM.
Ig Type
IgG
Reactivity
Human,Mouse,Rat
Application
Recommended Dose
WB: 1:1000-2000; IHC: 1:100-500; ICC/IF: 1:100-500; FCM: 1:50-100
Antibody Type
Monoclonal
Host SpeciesRabbit
ConstructionRecombinant Antibody
PurificationProA affinity purified
AppearanceLiquid
Formulation1*TBS (pH7.4), 1%BSA, 40%Glycerol. Preservative: 0.05% Sodium Azide.
Research BackgroundPARK7/DJ1 is a ubiquitously expressed protein involved in various cellular processes including cell proliferation, RNA-binding, and oxidative stress. The protein has been found to colocalize within a subset of pathologic tau inclusions in a diverse group of neurodegenerative disorders known as tauopathies. Defects in PARK7/DJ1 are the cause of autosomal recessive early-onset Parkinson's disease 7 (PARK7). Parkinson's disease (PD) is a complex, multifactorial disorder that typically manifests after the age of 50 years. The disease is characterized by bradykinesia, resting tremor, muscular rigidity and postural instability. The pathology involves the loss of dopaminergic neurons in the substantia nigra and the presence of Lewy bodies (intraneuronal accumulations of aggregated proteins), in surviving neurons in various areas of the brain. PARK7 is characterized by onset before 40 years and slow progression. It has also been suggested that PARK7/DJ1 is a mitogen dependent oncogene product involved in Ras related signal transduction pathways.
Related Conjugates and Formulations
Conjucates
Unconjugated
Antigen Details
Immunogen
Recombinant Protein
Antigen Species
Recombinant Protein
Uniprot ID
Chemical Properties
Molecular WeightTheoretical: 20 kDa.
Stability & Storage
Stability & StorageStore at -20°C or -80°C for 12 months. Avoid repeated freeze-thaw cycles.
TransportShipping with blue ice.

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

Sci Citations

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Related Tags: buy Anti-PARK7/DJ1 Antibody (9Q473) | purchase Anti-PARK7/DJ1 Antibody (9Q473) | Anti-PARK7/DJ1 Antibody (9Q473) cost | order Anti-PARK7/DJ1 Antibody (9Q473) | Anti-PARK7/DJ1 Antibody (9Q473) molecular weight